Amgen on Friday earned expanded FDA approval for its drug Xgeva, reports Reuters.
Here are four things to know.
1. Xgeva is already approved to treat hypercalcemia and giant cell tumor of the bone, and prevent skeletal-related events in patients with bone cancers.
2. Now, the drug may also be used to prevent bone fractures in patients with multiple myeloma.
3. Amgen reacquired the rights to Xgeva in 2015 through a deal with GlaxoSmithKline.
4. The drug generated $1.53 billion in sales for Amgen in 2016.
More articles on supply chain:
FDA ends 2017 with 46 new drug approvals – the most in 2 decades
California city could be first in US to use drones to deliver blood
Mold-contaminated antibiotic recalled nationwide: 5 things to know